The cytokines that contribute to airway in¯ammation, including interleukin-1b (IL-1b)and tumour necrosis factor a (TNFa), might have key roles in the development of chronic obstructive pulmonary disease (COPD). Interleukin-1 receptor antagonist (ILÐ1RN), the physiological antagonist of IL-1b, is also known to play a crucial role in several chronic in¯ammatory diseases. In this study, we investigated the association of the polymorphisms of IL-1b, IL-1RN and TNFa with susceptibility to COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible air¯ow limitation in the lungs (1) . The most important risk factor for development of COPD is tobacco smoking. However, the fact that only 10±20% of chronic heavy smokers develop symptomatic COPD (2, 3) suggests that dierences of susceptibility to tobacco smoke injury must exist, and the genetic factors are supposed to be related to this individual susceptibility. Furthermore, the recent study suggested that familial factors other than protease inhibitor type might in¯uence the development of air¯ow obstruction and chronic bronchitis (4) .
Interleukin -1b (IL-1b) is a member of the interleukin-1 family that has a broad spectrum of both bene®cial and harmful biological actions. It is rapidly synthesized by monocytic phagocytes, which are major cellular components of bronchoalveolar lavage of current smokers, when they have been stimulated by microbial products or in¯ammation. IL-1b is supposed to be one of the important cytokines in irreversible airway obstruction in long-standing asthma- (5) . IL-1b is also known to increase the synthesis of the collagenase (6) that was reported to cause the development of emphysema of mouse lungs (7) .
Polymorphisms of IL-1b have been reported; a single base polymorphism at -511 (8) and a biallelic polymorphism in exon-5 de®ned by a silent T?C transition (9) . Mononuclear cells carrying one or two copies of the wildtype alleles in exon-5 were reported to produce increased amounts of IL-1b protein when stimulated with lipopolysaccharide (9) .
The interleukin-1 receptor antagonist (IL-1RN) is a protein that binds to IL-1 receptor, which inhibits the binding of IL-1a and IL-1b to the IL-1 receptor. As a consequence, the biological activity of these cytokines is neutralized in physiological and/or pathological immune and in¯ammatory responses.
The IL-1RN polymorphism is characterized by two to six repeats (variable number of tandem repeats, VNTR) of the 86-bp-long segment in the second intron of the gene (10) . The four-repeat allele (IL-1RN*1) is the most frequent allele. In contrast, the two-repeat allele (IL-1RN*2), the second most frequent allele, was found to be associated with more severe clinical outcome in several chronic in¯ammatory diseases, including systemic lupus erythematosus (11), ulcerative colitis (12) , alopecia areata (13) , and diabetic nephropathy (14) .
Tumour necrosis factor a (TNFa) is also the major cytokine that contributes to the airway in¯ammation. A single base polymorphism at 7308 of TNFa has been described (15) . Recently, it has been reported that carriage of the less common A allele confers a higher risk to the development of chronic bronchitis (16) . Although chronic bronchitis is a part of COPD, the association of polymorphism of TNFa with susceptibility to COPD, or tobacco-induced airway in¯ammation, has not been yet con®rmed.
In the current study, we investigated whether the polymorphisms of IL-1b, IL-1RN and TNFa gene have an association with development of COPD among smokers by polymerase chain reaction (PCR)-based genotyping assay.
Materials and methods

STUDY SUBJECTS
The patient group consisted of 53 male adults with COPD, diagnosed in the Tokyo University Hospital and the Juntendo University Hospital according to the guidelines of the European Respiratory Society (1) . The diagnosis was based on signs and symptoms, the pulmonary function test (including %FEV 1?0 , RV/TLC, DL CO ) in the stable condition and chest X-ray (including CT). There were no asthma patients in the COPD group. Three quarters of COPD patients were treated with methylxanthine, 2/3 with inhaled anti-cholinergic agents, 1/4 with inhaled badrenergic agonist and inhaled corticosteroid, 15% with oral b-adrenergic agonist and less than 10% with oral prednisone. The serum level of a 1 -antitrypsin in the COPD group was within normal range [mean value 254?0 (SE 7?4 )(range: 159±391) mg dl 71 ]. Sixty-®ve blood samples of control subjects were obtained from the Health Check Division at the Tokyo Kenbikyoin Clinic. None of them had family members aected by COPD. To exclude the eects of gender dierence and to match the smoking history, all of them were male and current smokers free from pulmonary diseases, and showed normal values in the pulmonary function tests.
STUDY DESIGN
Genomic DNA was extracted from whole blood by QIAamp Blood Kit (QIAGEN Inc., CA, U.S.A). PCR and restriction enzyme fragment length polymorphism (RFLP) assays were performed to genotype the IL-1b polymorphisms at position 7511 base and at the amino acid residue 105, the IL-1RN polymorphism in intron 2, and TNFa polymorphism at position 7308. The primers used for each PCR, annealing temperature and cycle number for PCR, the restriction enzymes for restriction enzyme length polymorphism (RFLP) and the length of expected bands are shown in Table 1 . AvaI was purchased from TAKARA Inc., Tokyo, Japan. All other restriction enzymes were purchased from New England BioLabs Inc, MA, U.S.A. 
PCR-BASED GENOTYPING ASSAY FOR IL1-, IL-1RN AND TNF POLYMORPHISM
PCRs were carried out with a Program-temp-control system PC-800 (Astec, Tokyo, Japan). Genomic DNA (100 ng) was added to a mixture containing 11 pmol of each primer, 0?5 U of AmpliTaq Gold with 1?5 m1 of 106PCR buer (containing 25 mM MgCl 2 ) and 1?5 ml of 106dNTPmix (Perkin-Elmer Applied Biosystems Division, CA, U.S.A) in a ®nal volume of 15 ml. The`auto-hot start' was used to prevent non-speci®c priming in the ®rst cycle of PCR. Following an initial denaturation step at 958C for 12 min, 35 cycles of PCR were carried out (denaturation at 958C for 30 sec, annealing for 30 sec, elongation at 728C for 60 sec),which were followed by 1 cycle of elongation at 728C for 5 min. The PCR products were digested with the restriction enzyme, except for the IL-1RN genotyping assay. All digests were electrophoresed on a gel with 3?5% Ultrapure Agarose (GibcoBRL, MD, U.S.A) containing ethidium bromide.
ANALYSIS
The dierences in allele distribution and allele frequency among each group were examined by the w 2 -test, with the Fisher exact test when appropriate. The age, smoking index expressed as pack-year (number of pack of tobacco smoked per day 6 number of years smoked), and the values of pulmonary function test in both COPD and control subjects were compared using the unpaired Student's t-test. These analyses were performed by Stat-View J-4.5 application program (SAS Institute Inc., NC, U.S.A.). P-values less than 0?05 were considered to be statistically signi®cant. All values are expressed as mean+SEM.
Results
Age, smoking history and results of pulmonary function test of the COPD patients and control group are shown in Table 2 . The dierence of the means of the pack-years of tobacco between these groups were not signi®cant. The mean of %FEV 1.0 of the COPD group was 50% of the control group (mean value 46?72?3%, 96?41?5% respectively).
The results of the IL-1b polymorphisms at position -511 base and at the amino acid residue 105, the IL-1RN polymorphism in intron 2, and TNFa polymorphism at position -308 are summarized in Tables 3, 4 and 5 respectively. In the control group, the major allele frequency of IL-1b polymorphisms at position 7511 base and TNFa polymorphism at position 7308 was 0?45 and 0?99, respectively. Our results agree with those obtained by previous reports in a Japanese population (17, 18) . The frequency of IL-1RN*1 was 0?93, and this was also similar to a previous Japanese report (19) . The major allele frequency of IL-1b polymorphisms at the amino acid residue 105 was 0?96, and this allele frequency has not yet been reported in a Japanese population, and was much higher than 0?74, the frequency in a Caucasian population (9) .
Genotype and allele frequencies as well as carriage rates of the two polymorphisms of IL-1b were similar in the COPD and control groups ( Table 3 ). There was also no signi®cant dierence on allele frequency of IL-1RN*2 and distribution of the genotype of IL-1RN between the two groups (Table 4 ). Furthermore, allele frequency of the polymorphism of TNFa was also similar in the COPD and control groups (Table 5 ).
Discussion
In this study, we investigated whether polymorphisms of IL-1b, IL-1RN and TNFa gene have an association with the development of COPD. In the view of statistics, given the large number of possible candidate genes for COPD, a signi®cance level of 5% will cause many false-positive results. However, we could not ®nd any dierences of the distribution of polymorphisms between the COPD and control groups. These cytokines and the antagonist were reported to be associated with many chronic in¯ammatory diseases, and these cytokines are also supposed to be involved in the in¯ammatory component of COPD (20) . Chronic tobacco smoking is the major risk factor of the development of COPD. However, only a small proportion of smokers actually exhibit air¯ow limitation. Other factors, particularly the genetic factors, are supposed to be related to this individual susceptibility to tobacco induced lung injury. Recently, genetic polymorphisms of cytochrome P450 (21) , microsomal epoxide hydrolase (mEPHX) (22) , were suggested to have an association with emphysema. In addition, TNFa, one of the important cytokines that have key roles in in¯ammation, was also reported to be associated with chronic bronchitis (16) .
Several studies on the polymorphisms of IL-1b were previously performed in relation to the in¯ammatory bowel disease (23), insulin-dependent diabetes mellitus (24) , and periodontal disease (25) . However, the results were controversial. The two-repeat allele of IL-1RN (IL-1RN*2) was also reported to be associated with more severe clinical outcome in several chronic in¯ammatory diseases, including systemic lupus erythematosus (11) , ulcerative colitis (12) , alopecia areata (13) and diabetic nephropathy (14) . The four-repeat (IL-1RN*1) and IL-1RN*2 alleles are most common. The repeat region of IL-1RN contains three potential protein-binding sites. Therefore, the variable copy number of this repeat region may have functional signi®cance (10) . Indeed, IL-1RN*2 was reported to be associated with increased production of IL-1RN protein, reduced production of IL-1a protein, and enhanced productionof IL-1b by monocytes in vitro (26, 27) . However, this study shows that there is no dierence on the distribution of polymorphism of IL-1b and IL-1RN between the COPD and control groups.
The TNFa gene is known to have the polymorphic site at position 7308 (15) . Although the actual eect of this polymorphism in vivo has not been clearly demonstrated, the less common A allele was shown to be a much more powerful transcriptional activator than the common allele (28) . Positive association with the A allele was found in some diseases, including cerebral malaria (29) , dermatitis herpetiformis (30) and chronic bronchitis (16) . However, we could not con®rm an association between the polymorphism at position 7308 of TNFa gene and COPD. Because chronic bronchitis may not exactly be the same as pulmonary emphysema in terms of pathophysiology and tobacco-sensitivity, the polymorphism of TNFa may be more related to infection-induced airway in¯ammation rather than tobacco smoke-induced alveolar destruction.
In conclusion, we found no dierence in distributions of the polymorphisms of IL-1b, IL-1RN and TNFa between the COPD and control groups. Since the number of the subjects examined in this study is limited, the further study using a larger population is needed and other variations in these genes should be investigated to clarify the association of these genes with individual susceptibility to development of COPD. Control group 57 (88%) 6 (9%) 1 (2%) 1 (2%) COPD Group 49 (92%) 3 (6%) 1 (2%) 0 (0%) 
